Andreas Hochhaus
Mannheim, BW 68167, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Cause and management of therapy resistance.
Journal: Best practice & research. Clinical haematology
Published: December 05, 2009
First-Line management of CML: a state of the art review.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 09, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Journal: Leukemia
Published: April 11, 2008
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Journal: Expert opinion on pharmacotherapy
Published: November 27, 2007
Management of Bcr-Abl-positive leukemias with dasatinib.
Journal: Expert review of anticancer therapy
Published: November 21, 2007
Resistance to targeted therapy in chronic myelogenous leukemia.
Journal: Seminars in hematology
Published: February 13, 2007
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Journal: Blood
Published: December 02, 2006
Therapy of chronic myelogenous leukemia in 2004
Journal: Deutsche medizinische Wochenschrift (1946)
Published: September 30, 2004
Clinical resistance to imatinib: mechanisms and implications.
Journal: Hematology/oncology clinics of North America
Published: July 24, 2004
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.
Journal: Leukemia
Published: June 25, 2004
Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group
Journal: Der Internist
Published: January 15, 2003
Last Updated: 09/26/2026